Navigation Links
Study Says Allergy Shots Help Children, Reduce Health Care Costs
Date:1/23/2008

BioMedEcon Study, First of its Kind in US, Finds Allergy Immunotherapy

Beneficial Even When Treatment Not Completed

MOSS BEACH, Calif., Jan. 23 /PRNewswire/ -- BioMedEcon, a leading provider of health economics and outcomes research, today announced findings of a landmark study which show allergy immunotherapy (IT) delivers important clinical benefits to children and significantly reduces health care costs, even when the appropriate course of treatment is not completed. The study of 520 low-income Florida children with allergic rhinitis found that IT was associated with significant savings across all aspects of the health care system -- inpatient, outpatient and medication treatments -- even among children who completed only a fraction of the recommended three-year treatment regimen. The study is published in the January 2008 issue of The Journal of Allergy and Clinical Immunology (JACI).

The BioMedEcon study, a first of its kind in the United States, examined nine years of data (1997-2006) on children in the Florida Medicaid program to compare health costs for the six-month period before the initiation of IT to the six-month period following IT discontinuation. Adherence to the treatment program was poor, with 39 percent of the children receiving less than six months of IT, and only 16 percent completing at least three years of IT. However, the study found that the benefits extended across children in the sample, with strikingly reduced numbers of hospitalizations, doctor's visits and prescription drugs following treatment.

"These findings are remarkable," said Cheryl S. Hankin, Ph.D., president and CSO of BioMedEcon, LLC. "Even though most of the children in our study had insufficient treatment duration, averaging less than half of the recommended course, their health care use and costs significantly declined following treatment. It is clear that allergy immunotherapy not only benefits children with allergic rhinitis, but delivers compelling cost savings to the health care system. We believe children and health care systems would benefit even more if treatment duration were sufficient."

"The research pioneered by BioMedEcon illustrates both the importance of allergy immunotherapy for children with allergies and the economic incentives for ensuring they are appropriately treated," said Robert Esch, Ph.D., Executive Vice President of Research and Development for Greer Laboratories, which sponsored the study. "These findings, which highlight the benefits for patients with allergies, their providers and insurers, will help drive and focus our efforts to provide patients easier access to treatment."

About Greer

Greer is a leading developer and provider of allergy immunotherapy products and services for treating humans and animals. Greer's highly skilled scientists provide technical support for customers by continuing to focus on improving the lives of allergic patients. Greer's clinical development programs are focused on expanding the use of immunotherapy through oral administration of allergy immunotherapy. Greer's goal is to establish the efficacy of standardized products for oral administration through clinical trials. The company was founded in 1904 and is located in Lenoir, N.C. For more information, visit http://www.greerlabs.com.

About BioMedEcon

Based in Moss Beach, California, privately-held BioMedEcon, LLC is a leading-edge provider of health economics and outcomes research. BioMedEcon applies rigorous scientific methods to create coherent, objective and practical formulary decision models, pharmaceutical and drug delivery market entry strategies, and healthcare policy recommendations. Clients and partners include established and emerging leaders in the pharmaceutical, biotech, drug delivery and medical device industries. For more information, call 650.563.9475 or visit http://biomedecon.com/. Additional study data and article reprints are available by emailing cherylhankin@biomedecon.com.


'/>"/>
SOURCE BioMedEcon, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
2. Mayo Clinic Study Finds Further Association Between Diabetes and Pancreatic Cancer
3. Divine Corporations Personal Lubricants Shown to Block Cancer-causing Viruses in a Study by the National Cancer Institute
4. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
5. Northwestern Memorial Transplant Program Initiates New Study
6. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
7. CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids
8. Study Reports Successful Cloning of Human Embryo Using Adult DNA
9. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
10. Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
11. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, ... Board will take whatever measures required to build a ... stock which is currently listed on the OTC Markets-pink ... Company Chairman and CEO, "We are seeing an anomaly ... to understand, not only by the Company, but shareholders ...
(Date:6/24/2016)... N.J. , June 24, 2016  Collagen ... the design, development and manufacturing of collagen and ... regeneration announced today that Bill Messer ... and Marketing to further leverage the growing portfolio ... medical devices. Bill joins the Collagen ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... and Markets has announced the addition of the ... their offering. ... products and provides an updated review, including its applications ... covering the total market, which includes three main industries: ...
Breaking Medicine Technology:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... "FCPX editors ... customizable inside of Final Cut Pro X," said Christina Austin - CEO of Pixel ... style. Final Cut Pro X users can now reveal the media of ...
(Date:6/26/2016)... (PRWEB) , ... June 27, 2016 , ... Quality metrics ... yet in many ways they remain in the eye of the beholder, according to ... a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... Birmingham, Lake Orion, Clarkston, Michigan (PRWEB) , ... ... ... their direction with respect to fertility once they have been diagnosed with endometriosis. ... for tolerable intercourse but they also require a comprehensive approach that can help ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
Breaking Medicine News(10 mins):